Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Oct 15;102(8):1559–1568. doi: 10.1172/JCI4164

Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice.

M M Véniant 1, C H Zlot 1, R L Walzem 1, V Pierotti 1, R Driscoll 1, D Dichek 1, J Herz 1, S G Young 1
PMCID: PMC509006  PMID: 9788969

Abstract

The role of the low density lipoprotein receptor (LDLR) in the clearance of apo-B48-containing lipoproteins and the role of the LDLR-related protein (LRP) in the removal of apo-B100-containing lipoproteins have not been clearly defined. To address these issues, we characterized LDLR-deficient mice homozygous for an "apo-B48-only" allele, an "apo-B100-only" allele, or a wild-type apo-B allele (Ldlr-/- Apob48/48, Ldlr-/-Apob100/100, and Ldlr-/-Apob+/+, respectively). The plasma apo-B48 and LDL cholesterol levels were higher in Ldlr-/-Apob48/48 mice than in Apob48/48 mice, indicating that the LDL receptor plays a significant role in the removal of apo-B48-containing lipoproteins. To examine the role of the LRP in the clearance of apo-B100-containing lipoproteins, we blocked hepatic LRP function in Ldlr-/-Apob100/100 mice by adenoviral-mediated expression of the receptor-associated protein (RAP). RAP expression did not change apo-B100 levels in Ldlr-/-Apob100/100 mice. In contrast, RAP expression caused a striking increase in plasma apo-B48 levels in Apob48/48 and Ldlr-/-Apob48/48 mice. These data imply that LRP is important for the clearance of apo-B48-containing lipoproteins but plays no significant role in the clearance of apo-B100-containing lipoproteins.

Full Text

The Full Text of this article is available as a PDF (364.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beisiegel U., Weber W., Ihrke G., Herz J., Stanley K. K. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature. 1989 Sep 14;341(6238):162–164. doi: 10.1038/341162a0. [DOI] [PubMed] [Google Scholar]
  2. Bu G. Receptor-associated protein: a specialized chaperone and antagonist for members of the LDL receptor gene family. Curr Opin Lipidol. 1998 Apr;9(2):149–155. doi: 10.1097/00041433-199804000-00012. [DOI] [PubMed] [Google Scholar]
  3. Davidson N. O., Anant S., MacGinnitie A. J. Apolipoprotein B messenger RNA editing: insights into the molecular regulation of post-transcriptional cytidine deamination. Curr Opin Lipidol. 1995 Apr;6(2):70–74. doi: 10.1097/00041433-199504000-00002. [DOI] [PubMed] [Google Scholar]
  4. Dong G., Schulick A. H., DeYoung M. B., Dichek D. A. Identification of a cis-acting sequence in the human plasminogen activator inhibitor type-1 gene that mediates transforming growth factor-beta1 responsiveness in endothelium in vivo. J Biol Chem. 1996 Nov 22;271(47):29969–29977. doi: 10.1074/jbc.271.47.29969. [DOI] [PubMed] [Google Scholar]
  5. Farese R. V., Jr, Véniant M. M., Cham C. M., Flynn L. M., Pierotti V., Loring J. F., Traber M., Ruland S., Stokowski R. S., Huszar D. Phenotypic analysis of mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6393–6398. doi: 10.1073/pnas.93.13.6393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Goldstein J. L., Brown M. S., Anderson R. G., Russell D. W., Schneider W. J. Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. Annu Rev Cell Biol. 1985;1:1–39. doi: 10.1146/annurev.cb.01.110185.000245. [DOI] [PubMed] [Google Scholar]
  7. Greeve J., Altkemper I., Dieterich J. H., Greten H., Windler E. Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J Lipid Res. 1993 Aug;34(8):1367–1383. [PubMed] [Google Scholar]
  8. Ishibashi S., Brown M. S., Goldstein J. L., Gerard R. D., Hammer R. E., Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 1993 Aug;92(2):883–893. doi: 10.1172/JCI116663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ishibashi S., Goldstein J. L., Brown M. S., Herz J., Burns D. K. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest. 1994 May;93(5):1885–1893. doi: 10.1172/JCI117179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ishibashi S., Herz J., Maeda N., Goldstein J. L., Brown M. S. The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4431–4435. doi: 10.1073/pnas.91.10.4431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ishibashi S., Perrey S., Chen Z., Osuga J. i., Shimada M., Ohashi K., Harada K., Yazaki Y., Yamada N. Role of the low density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. A quantitative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both. J Biol Chem. 1996 Sep 13;271(37):22422–22427. doi: 10.1074/jbc.271.37.22422. [DOI] [PubMed] [Google Scholar]
  12. Kane J. P. Apolipoprotein B: structural and metabolic heterogeneity. Annu Rev Physiol. 1983;45:637–650. doi: 10.1146/annurev.ph.45.030183.003225. [DOI] [PubMed] [Google Scholar]
  13. Kim E., Cham C. M., Véniant M. M., Ambroziak P., Young S. G. Dual mechanisms for the low plasma levels of truncated apolipoprotein B proteins in familial hypobetalipoproteinemia. Analysis of a new mouse model with a nonsense mutation in the Apob gene. J Clin Invest. 1998 Mar 15;101(6):1468–1477. [PMC free article] [PubMed] [Google Scholar]
  14. Kim E., Young S. G. Genetically modified mice for the study of apolipoprotein B. J Lipid Res. 1998 Apr;39(4):703–723. [PubMed] [Google Scholar]
  15. Kowal R. C., Herz J., Goldstein J. L., Esser V., Brown M. S. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc Natl Acad Sci U S A. 1989 Aug;86(15):5810–5814. doi: 10.1073/pnas.86.15.5810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Linton M. F., Farese R. V., Jr, Chiesa G., Grass D. S., Chin P., Hammer R. E., Hobbs H. H., Young S. G. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J Clin Invest. 1993 Dec;92(6):3029–3037. doi: 10.1172/JCI116927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Linton M. F., Hasty A. H., Babaev V. R., Fazio S. Hepatic apo E expression is required for remnant lipoprotein clearance in the absence of the low density lipoprotein receptor. J Clin Invest. 1998 Apr 15;101(8):1726–1736. doi: 10.1172/JCI2181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Mahley R. W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988 Apr 29;240(4852):622–630. doi: 10.1126/science.3283935. [DOI] [PubMed] [Google Scholar]
  19. Mahley R. W. Heparan sulfate proteoglycan/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer's disease. Isr J Med Sci. 1996 Jun;32(6):414–429. [PubMed] [Google Scholar]
  20. Marcel Y. L., Innerarity T. L., Spilman C., Mahley R. W., Protter A. A., Milne R. W. Mapping of human apolipoprotein B antigenic determinants. Arteriosclerosis. 1987 Mar-Apr;7(2):166–175. doi: 10.1161/01.atv.7.2.166. [DOI] [PubMed] [Google Scholar]
  21. Milne R. W., Weech P. K., Blanchette L., Davignon J., Alaupovic P., Marcel Y. L. Isolation and characterization of apolipoprotein B-48 and B-100 very low density lipoproteins from type III hyperlipoproteinemic subjects. J Clin Invest. 1984 Mar;73(3):816–823. doi: 10.1172/JCI111276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mokuno H., Brady S., Kotite L., Herz J., Havel R. J. Effect of the 39-kDa receptor-associated protein on the hepatic uptake and endocytosis of chylomicron remnants and low density lipoproteins in the rat. J Biol Chem. 1994 May 6;269(18):13238–13243. [PubMed] [Google Scholar]
  23. Powell-Braxton L., Véniant M., Latvala R. D., Hirano K. I., Won W. B., Ross J., Dybdal N., Zlot C. H., Young S. G., Davidson N. O. A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet. Nat Med. 1998 Aug;4(8):934–938. doi: 10.1038/nm0898-934. [DOI] [PubMed] [Google Scholar]
  24. Purcell-Huynh D. A., Farese R. V., Jr, Johnson D. F., Flynn L. M., Pierotti V., Newland D. L., Linton M. F., Sanan D. A., Young S. G. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest. 1995 May;95(5):2246–2257. doi: 10.1172/JCI117915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Raabe M., Flynn L. M., Zlot C. H., Wong J. S., Véniant M. M., Hamilton R. L., Young S. G. Knockout of the abetalipoproteinemia gene in mice: reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8686–8691. doi: 10.1073/pnas.95.15.8686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Rohlmann A., Gotthardt M., Hammer R. E., Herz J. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest. 1998 Feb 1;101(3):689–695. doi: 10.1172/JCI1240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Schneeman B. O., Kotite L., Todd K. M., Havel R. J. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):2069–2073. doi: 10.1073/pnas.90.5.2069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Tsukamoto K., Smith P., Glick J. M., Rader D. J. Liver-directed gene transfer and prolonged expression of three major human ApoE isoforms in ApoE-deficient mice. J Clin Invest. 1997 Jul 1;100(1):107–114. doi: 10.1172/JCI119501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Véniant M. M., Pierotti V., Newland D., Cham C. M., Sanan D. A., Walzem R. L., Young S. G. Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. J Clin Invest. 1997 Jul 1;100(1):180–188. doi: 10.1172/JCI119511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Walzem R. L., Davis P. A., Hansen R. J. Overfeeding increases very low density lipoprotein diameter and causes the appearance of a unique lipoprotein particle in association with failed yolk deposition. J Lipid Res. 1994 Aug;35(8):1354–1366. [PubMed] [Google Scholar]
  31. Willnow T. E., Armstrong S. A., Hammer R. E., Herz J. Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo. Proc Natl Acad Sci U S A. 1995 May 9;92(10):4537–4541. doi: 10.1073/pnas.92.10.4537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Willnow T. E., Sheng Z., Ishibashi S., Herz J. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science. 1994 Jun 3;264(5164):1471–1474. doi: 10.1126/science.7515194. [DOI] [PubMed] [Google Scholar]
  33. Young S. G. Recent progress in understanding apolipoprotein B. Circulation. 1990 Nov;82(5):1574–1594. doi: 10.1161/01.cir.82.5.1574. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES